These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-007928-18 Evaluation of efficacy and safety of the herbal drug Myrrhinil-Intest vs. mesalazine in maintaining clinical remission of ulcerative colitis - a 12-month, multicenter, randomized, prospective, double-... 2010-08-31 due-trials
Not reported 2010-022096-54 Randomised, prospective, double-dummy double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus standard antibiotics in the treatment of acute uncomplicated cystitis 2013-06-05 due-trials
Not reported 2010-023227-26 Randomized, prospective double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus placebo in the prophylaxis of respiratory tract infections 2011-05-02 due-trials
Ongoing 2013-004653-25 Clinical trial for examination of efficacy and safety of ANGOCINĀ® Anti-Infekt N versus placebo in the continous prophylaxis of chronically recurring uncomplicated cystitis not-yet-due
Ongoing 2014-003024-46 Efficacy, safety and tolerability of Angocin Anti-Infekt N versus Placebo for MRSA eradication not-yet-due
Ongoing 2016-004842-27 Clinical Trial to investigate the efficacy and safety of ANGOCINĀ® Anti-Infekt N versus placebo in the prophylaxis of catheter associated urinary tract infections not-yet-due
Ongoing 2016-005063-13 Investigation of Efficacy, Safety, Acid Resistance and Mode of Action of Lipases in Nortase and Kreon with the Pancreo-Lip 13C breath test in Subjects with Severe Exocrine Pancreatic Insufficiency not-yet-due
Not reported 2017-002081-40 Investigation of the efficacy and safety of ANGOCINĀ® Anti-Infekt N versus placebo in adult patients with acute, uncomplicated rhinosinusits. A multi-center, randomized, double-blind, placebo-controlle... 2018-03-28 due-trials